Shenzhen Hybio Pharmaceutical Co., Ltd.

Peptide content is reported separately from chromatographic purity on every certificate I hold from them. Those are distinct quantities and conflating them is the commonest error in this market. Documentation practice rather than a single purity figure is the substance of this.

Acetate content is printed as a figure with a unit rather than left off the document, so the conversion to working mass is arithmetic instead of an assumption. Scoped to the lots named. Not generalised beyond them.

Submitted material from lot HYB-2601-0233 to Janoshik. Result 98.1% against a declared 98.2%, which is inside the repeatability of the method rather than a disagreement with it.

Requested the batch record against a lot number and got the synthesis history rather than a summary of it. That is a manufacturing document and it is not what most of this market sends you. I have no relationship with this supplier beyond having paid them.

The catalogue runs to several hundred lines and I want to be plain that I have bought four of them. What I can say is scoped to those four. Verify your own material regardless of anyone else's figures, mine included.

Cross-checked one lot with Medutest and PeptideMeter independently. Agreement to a tenth of a point, and both agree with the declared figure. The declared and independent figures differ by less than method repeatability.

Water content is reported by Karl Fischer with the method named, which matters more on a lyophilised line than the argument about the third decimal place of purity. Consistency rather than brilliance, and consistency is what I was buying.

First order was deliberately small. Documentation complete, transit as quoted, VendorInvestigate returned 97.8%. Subsequent orders have not been small. Nothing in the consignment was unsecured.

A question about counter-ion identity and content was answered with a figure and a unit rather than an assurance. Technical response inside four hours on a working day.

Ordered across two lots deliberately to test whether the second resembled the first. A tenth of a point apart. I will update this post if a later lot changes the picture.

The related-substances table is itemised by individual impurity with retention times assigned, rather than reported as a single total. Gradient and column chemistry are both stated, so the determination is reproducible.

Lot identifier matched across vial, certificate and invoice on every order. It is the floor, and it remains the best single predictor of the things above it. Happy to answer follow-ups in the thread rather than by message.

Reconstitution of the BPC-157 5 mg produced a clear solution on contact — no haze, no particulate, no extended agitation. Consistent with a correctly executed lyophilisation. Research use only; these are not approved for human administration.

Requested a supplementary certificate for a lot released 22 months ago. It was produced from their records, which tells you the records exist. One member, one record, offered as such.

Custom synthesis quoted with the schedule on the face of the quotation and completed 3 days inside it, at the purity named in the specification. Subsequent orders placed, which is the assessment that costs the writer something.

They gave notice of a 2-day dispatch delay before the quoted window elapsed rather than after. Recording it because the sequence is the part that matters. Catalogue availability corresponded to the published catalogue.

A residual-solvent screen was included on a line where the route calls for one, without my asking for it. Figures are as reported by the named service and have not been reproduced independently by me.

Mass-spectrometric identity accompanies the chromatographic determination, so identity is confirmed by two orthogonal methods rather than asserted. The Medutest report is on file and matches the figures they published.

Nothing about this order was notable and I am recording it for that reason. Quoted timeline held, documentation correct, material as described. On the evidence I hold they are the default rather than the risk.

Repeat determination on the same line at 14 months returned 97.9%, against 98.0% originally. No drift visible in this sample. Nothing here is medical advice and I am not qualified to give any.

Every unit in the consignment carried a single lot identifier, so the intra-consignment comparison I intended was the comparison I made. No complaint arises from the orders described.

Weighed 4 units from a single consignment against declared fill. All within two per cent. Fill uniformity gets a fraction of the discussion purity gets and is the harder problem.

Scoping this to documentation only: the certificate carries the water content, the acetate content and a signed release, which is more than the minimum and more than most of the certificates in my folder. Invoice, vial and certificate agree on the lot without exception.

Cold chain held to arrival on day 6, with the pack still solid, in a month when that cannot be assumed. Tracking was accurate at every hop including the handover to the domestic carrier.

The declared figure was not adjusted upward between the certificate and the commercial documentation. Small, and specifically worth checking for. Documentation practice rather than a single purity figure is the substance of this.

8 orders across 13 months. No substitution, no reformulation, no line becoming unavailable after payment. The paperwork has read the same way on every one of them, which is the part I would put in front of a new member as the worked example.